Mednax Inc
$ 19.29
-2.97%
05 Mar - close price
- Market Cap 1,707,242,000 USD
- Current Price $ 19.29
- High / Low $ 19.85 / 18.88
- Stock P/E 10.25
- Book Value 10.68
- EPS 1.94
- Next Earning Report 2026-05-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.07 %
- ROE 0.20 %
- 52 Week High 24.99
- 52 Week Low 11.84
About
MEDNAX, Inc., provides neonatal, maternal-fetal, pediatric cardiology, and other pediatric subspecialties in the United States and Puerto Rico. The company is headquartered in Sunrise, Florida.
Analyst Target Price
$21.33
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-19 | 2025-10-30 | 2025-08-05 | 2025-05-05 | 2025-02-18 | 2024-11-01 | 2024-08-06 | 2024-05-07 | 2024-02-20 | 2023-11-02 | 2023-08-03 | 2023-05-02 |
| Reported EPS | 0.5 | 0.67 | 0.53 | 0.2427 | 0.51 | 0.44 | 0.34 | 0.2 | 0.32 | 0.32 | 0.39 | 0.23 |
| Estimated EPS | 0.538 | 0.4379 | 0.42 | 0.2646 | 0.3646 | 0.37 | 0.31 | 0.19 | 0.33 | 0.43 | 0.4 | 0.23 |
| Surprise | -0.038 | 0.2321 | 0.11 | -0.0219 | 0.1454 | 0.07 | 0.03 | 0.01 | -0.01 | -0.11 | -0.01 | 0 |
| Surprise Percentage | -7.0632% | 53.003% | 26.1905% | -8.2766% | 39.8793% | 18.9189% | 9.6774% | 5.2632% | -3.0303% | -25.5814% | -2.5% | 0% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-12 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.3111 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MD
2026-03-05 10:51:13
JPMorgan Chase & Co. has significantly increased its stake in Pediatrix Medical Group, Inc. (NYSE:MD) by 20.5%, now holding 827,075 shares valued at $13.85 million. This represents approximately 0.95% of the company, which recently reported Q3 earnings with a slight EPS miss but beat revenue expectations. Institutional ownership of Pediatrix is notably high at 97.71%, while insiders hold 0.90%, following a recent share sale by CEO Mark S. Ordan.
2026-03-05 02:51:13
Pediatrix Medical Group (MD) recently reported a return to annual profitability in Q4 2025, with net income of US$165.39 million for the full year, a significant improvement from a US$99.07 million loss in 2024. This, coupled with substantial share repurchase programs, including the retirement of over 4 million shares, could positively impact per-share earnings and financial flexibility for investors. However, the company still faces challenges such as year-on-year revenue softness and potential pressures from rising salary and staffing costs.
2026-03-04 01:52:19
Pediatrix Medical Group (MD) has seen a recent share price weakness, with a 7% drop over the past month and 17% over three months, despite positive one-year and three-year returns. The stock is currently trading at US$19.85, below a fair value estimate of $22.67, suggesting it is undervalued by approximately 12.4%. Investors are encouraged to review the company's risk and reward profile, considering potential for operational efficiencies and strategic growth against challenges like staff cuts and rising costs.
2026-03-03 21:51:36
Pediatrix Medical Group EVP and General Counsel Mary Ann E. Moore was awarded 39,925 shares of company common stock on March 1, 2026, as part of a performance-based program. On the same date, 26,931 shares were withheld to cover tax obligations upon vesting, at a price of $19.85 per share. Following these transactions, Ms. Moore directly holds 149,236 shares, with an additional 52,598 shares held indirectly through a trust.
2026-02-26 12:51:46
Pediatrix Medical Group, Inc. reported mixed financial results for the quarter ending December 2025, with strong operating cash flow and a low debt-equity ratio, but a decline in quarterly net profit. While the company has outperformed the S&P 500 over the past year, its three-year performance lags, highlighting the need to address short-term profitability challenges. The company's financial trend has been adjusted due to these varied results, emphasizing both its strengths in liquidity and capital efficiency, and its weaknesses in maintaining consistent quarterly profits.
2026-02-26 00:52:01
This article provides a detailed financial analysis of Pediatrix Medical Group, Inc. (MD), covering its income statement, balance sheet, cash flow, and key financial ratios. It highlights the company's financial health with scores for profitability, growth, leverage, liquidity, and returns, noting its strong Piotroski F-Score and cash-backed earnings quality for fiscal year 2025.
